Biosimilar drug: Why cheap medicine is slow to take off in Europe

03-12-2013 FirstpostComments (0)


These cheaper versions of expensive biotech drugs, known as biosimilars, could slash the cost of treating diseases like cancer and rheumatoid arthritis in the same way that generics have curbed spending on traditional medicines. But although Europe has ...

Read more on Firstpost

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top